1. Executive Summary
2. Research Methodology
3. Introduction
4. Global Biologics Market
4.1 OVERVIEW
4.1.1 Classification of Biologics
4.2 GLOBAL BIOLOGICS MARKET ANALYSIS
1.1.1 Market Sizing (Actual & Forecasted)
5. Global Biosimilars Market
5.1 OVERVIEW
5.2 MARKET ANALYSIS
5.2.1 Market Sizing (Actual & Forecasted)
2.1.1 Market Share by Region (Actual & Forecasted)
3.1.1 Market Share by Application (Actual & Forecasted)
4.1.1 Market by Product Pipeline
6. Global Biosimilars Market Segmentation
6.1 ERYTHROPOIETIN (EPO)
6.1.1 Overview
6.1.2 Market Analysis
6.2 INSULIN
6.2.1 Overview
6.2.2 Market Analysis
6.3 HUMAN GROWTH HORMONE (HGH)
6.3.1 Overview
6.3.2 Market Analysis
6.4 GRANULOCYTE- COLONY STIMULATING FACTOR (G-CSF)
6.4.1 Overview
6.4.2 6.4.2 Market Analysis
6.4.2 6.4.2 Market Analysis
6.5 MONOCLONAL ANTIBODY (MAB)
6.5.1 Overview
6.5.2 Market Analysis
6.6 INTERFERON (IFN)
6.6.1 6.6.1 Overview
6.6.2 Market Analysis
7. Global Biosimilars Market Analysis - Developed & Emerging Nations
7.1 DEVELOPED MARKET
7.1.1Europe
7.1.2 The US
7.2 EMERGING MARKET
7.2.1 China
7.2.2India
8. Global Biosimilars - Pricing Analysis
9. Global Biosimilar Industry - SWOT Analysis
10. Global Biosimilars Market Attractiveness Index
11. Global Biosimilars Market Dynamics
11.1 INDUSTRY TRENDS & DEVELOPMENTS
11.1.1 New Biosimilars Dominated by Large Globals
11.1.2 11.1.2 Biosimilar Interchangeability Guidance by FDA
11.1.3 11.1.3 Focus on Pharmerging Markets
11.2 GROWTH DRIVERS
11.2.1 11.2.1 Biological Patent Expiries
11.2.2 11.2.2 Cost saving
11.2.3 11.2.3 Increased use for Treatment of Chronic Diseases
11.3 CHALLENGES
11.3.1 11.3.1 High Cost of Development
11.3.2 11.3.2 Regulatory Uncertainty
11.3.3 11.3.3 Lower Adoption Rate of Biosimilars
11.3.4 11.3.4 Manufacturer Skills Gap
12. Competitive Landscape
12.1 MARKET SHARE BY COMPETITORS
12.2 MARKET SHARE BY DRUGS
13. Company Profiles
13.1 SANDOZ
13.2 HOSPIRA
13.3 TEVA
13.4 CELLTRION
13.5 BIOCAD
13.6 DONG-A PHARMACEUTICAL CO., LTD
13.7 STADA